ArticleScientific reports2025
Anatomic feasibility of the WeFlow-JAAA endograft system for treating juxtarenal and pararenal abdominal aortic aneurysms.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the anatomic feasibility of a novel off-the-shelf device (modular endograft with superior mesenteric artery fenestration, celiac scallop, and bilateral renal inner branches) designed for the treatment of juxtarenal and pararenal abdominal aortic aneurysms (AAAs). Digital computed tomography angiograms were analyzed from 170 consecutive patients with juxtarenal or pararenal AAAs who participated in imaging screening for a national multicenter clinical trial assessing the effectiveness of the WeFlow-JAAA system between February 2022 and January 2024. Anatomic feasibility was evaluated in accordance with the investigational protocols and the instructions for use. A proximal seal of ≥ 20 mm was achieved in 98.2% of patients, and renovisceral artery incorporation was observed in 73.5% (125/170) of cases. According to the conservative instructions for use (IFU) criteria, anatomic feasibility was achieved in 34.7% (95%CI: 27.5%~41.9%) of patients. When applying the liberal IFU criteria, the suitability rate increased to 64.1% (95%CI: 56.8%~71.4%), with configurations A and B being suitable for 56.5% and 60.6% of cases, respectively. The WeFlow-JAAA endograft system exhibits a suitability rate of 64.1% for treating JRAAAs and PRAAAs with a healthy sealing zone of at least 5 mm below the SMA within the Chinese population. Nevertheless, the current design does not optimally allow for the incorporation of renovisceral arteries, indicating a need for further technical research in this domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.